drugset / Trial / NCT01449591

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591

Phase 2 Completed 36 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of treatment as compared to an active control and vehicle in patients with erythemato-telangiectatic rosacea.

Timeline

Start
2011-09
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BFH772 Small molecule 1 %
Comparator Metronidazole Small molecule 1 %

Indications